Cargando…
Moyamoya Biomarkers
Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recen...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Neurosurgical Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502237/ https://www.ncbi.nlm.nih.gov/pubmed/26180608 http://dx.doi.org/10.3340/jkns.2015.57.6.415 |
_version_ | 1782381169852022784 |
---|---|
author | Smith, Edward R. |
author_facet | Smith, Edward R. |
author_sort | Smith, Edward R. |
collection | PubMed |
description | Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use. |
format | Online Article Text |
id | pubmed-4502237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | The Korean Neurosurgical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-45022372015-07-15 Moyamoya Biomarkers Smith, Edward R. J Korean Neurosurg Soc Pediatric Issue Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use. The Korean Neurosurgical Society 2015-06 2015-06-30 /pmc/articles/PMC4502237/ /pubmed/26180608 http://dx.doi.org/10.3340/jkns.2015.57.6.415 Text en Copyright © 2015 The Korean Neurosurgical Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pediatric Issue Smith, Edward R. Moyamoya Biomarkers |
title | Moyamoya Biomarkers |
title_full | Moyamoya Biomarkers |
title_fullStr | Moyamoya Biomarkers |
title_full_unstemmed | Moyamoya Biomarkers |
title_short | Moyamoya Biomarkers |
title_sort | moyamoya biomarkers |
topic | Pediatric Issue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502237/ https://www.ncbi.nlm.nih.gov/pubmed/26180608 http://dx.doi.org/10.3340/jkns.2015.57.6.415 |
work_keys_str_mv | AT smithedwardr moyamoyabiomarkers |